Search results: (10000)
News Safety of Long-Term Therapy with Bevacizumab in Oncological Patients
The angiogenesis inhibitor bevacizumab is typically administered long-term. Therefore, a study published in the journal The Oncologist deals specifically with its long-term safety and tolerability in patients with various types of solid tumors.
News Current Legislative Changes Relating to Medical Devices – Overview Summary in a Nutshell
In 2022, several legislative changes were introduced in the area of medical devices (MD) for moist wound care. We are summarizing the news from three sectors, as presented by Mgr. Jan Zahálka at the Interdisciplinary Cooperation in the Treatment of Wounds and Skin Defects congress in 2022: prescribing MD by nurses, European Union Medical Device Regulation (MDR), and the issue of MD as potential hazardous waste.
News How Do Patients Themselves Perceive Today's Treatment Options for ITP and What Are Their Biggest Fears?
What is the perception and view of the treatment options for immune thrombocytopenia (ITP) from the patients' perspective, what do they fear, what approaches do they prefer, and why? Lozano et al. included a discussion on this topic in their review article for Expert Review of Hematology, which can be helpful in clinical practice for better understanding patients' needs and adjusting treatment algorithms.
News Geriatrics and Nutrition in Old Age - Invitation
We invite you to watch a webinar dedicated to the topic of nutrition in old age. The impetus for its creation was the fact that from September 1, 2020, physicians specializing in geriatrics are allowed to prescribe outpatient sipping to ensure early nutritional intervention for malnourished patients.
News Parenteral Nutrition as Part of Cancer Patient Treatment
Malnutrition represents a potentially serious complication for cancer patients. If it is not possible to meet the nutritional demands of the body through the enteral route, parenteral nutrition must be initiated. A doctor will recommend it in situations where the patient is at risk from the consequences of malnutrition. Up to 45% of these patients struggle with at least a 10% loss of their body weight.
News Improvement of Joint and Skin Symptoms and Their Contribution to Improving the Quality of Life in Patients with Psoriatic Arthritis
The cause of reduced quality of life in patients with psoriatic arthritis is the involvement of both skin and joints. Commonly used therapy certainly improves symptoms of both systems to some extent, but to what extent does this improvement correlate with a higher health-related quality of life? This question was addressed by analyzing two randomized studies.
News Pitfalls of Levothyroxine Replacement Therapy
Hypothyroidism (reduced function of the thyroid gland) affects approximately 1-2% of the population. Its prevalence increases with age and it is more common in women. Synthetic thyroid hormone levothyroxine is used to treat hypothyroidism. It is a widely prescribed medication available in tablets of various strengths.
News Is long-term treatment with ixekizumab sufficiently safe?
Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A poster presented at last year's European Academy of Dermatology and Venereology (EADV) congress summarizes ixekizumab safety data from monitoring lasting up to 5 years, based on nearly 18,000 patient-years (PY) in the treatment of this disease.
News Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis
How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)? Data from over 10 years of follow-up in patients with both radiographic and non-radiographic forms of axSpA were recently published in the journal Therapeutic Advances in Musculoskeletal Disease as part of the extended clinical trial ESTHER.
News Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Turkish authors in their study focused on the use of metamizole in addressing vasospasm in microsurgery. Using an animal model, they sought to answer the question of how this drug compares to lidocaine and papaverine.
News Efficacy and Safety of an Activated FXII Inhibitor in Preventing HAE Attacks
Hereditary angioedema (HAE) is a rare, potentially life-threatening inherited disorder characterized by dysregulation of the kallikrein-kinin system. This results in excessive production of bradykinin, which is responsible for soft tissue edema. Garadacimab, a human antibody inhibiting activated factor XII, is utilized in the prevention of these attacks. Its efficacy and safety were verified in a phase III clinical trial.
News Subcutaneous pdC1-INH in Patients with Hereditary Angioedema in Real-World Practice
Italian authors published a series of cases of patients with hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE) with long-term prophylaxis using human plasma-derived C1 inhibitor concentrate (pdC1-INH) in subcutaneous form. They supplement the results of the placebo-controlled COMPACT study, in which s.c. pdC1-INH reduced the frequency of attacks, with insights from real-world practice in 5 patients treated at the angioedema therapy center in Milan, Italy.
News Current ASH Guidelines for Management of ITP 2019 − Recommendations for Newly Diagnosed ITP in Adults
The American Society of Hematology (ASH) published current guidelines for immune thrombocytopenia (ITP) at the end of 2019, where a panel of experts attempted to define evidence-based recommendations for the management of these patients.
News New Therapeutic Options in Light of Current Knowledge on the Pathogenesis of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itching and recurrent eczematous lesions. AD is diagnosed in 2 out of 10 children and often persists into adulthood. In developed countries, it is the most common skin disease with a lifetime prevalence exceeding 15%. However, it is also very diverse due to a wide range of clinical phenotypes reflecting various pathophysiological mechanisms and interactions between genetics, the immune system, and the environment. So, what have we learned about atopic dermatitis from recent research, and how has this translated into advances in its treatment?
News Current and Future Possibilities for Influencing Immune Thrombocytopenia
The possibilities for treating immune thrombocytopenia (ITP) are quite broad today, with a major advancement for many patients being the advent of thrombopoietin receptor agonists. However, for some patients, optimal treatment is still not available, and their hope lies in further research.
News Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk
Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum thyroid-stimulating hormone (TSH) levels outside the normal range at some point. The negative effect of TSH levels above the upper reference limit is well documented, but according to two recently published population studies, mortality in patients treated with levothyroxine is also increased when TSH levels are below the lower reference limit.
News Micronized Diosmin Obtained Reimbursement, Based on Its Therapeutic Interchangeability with MPFF
On January 11, 2022, the State Institute for Drug Control (SÚKL) issued a decision on the determination of the amount and conditions of reimbursement from health insurance for a drug containing micronized diosmin. The reimbursement is valid from March 1, 2022.
News H₂FPEF Score for Estimating the Probability of Heart Failure with Preserved Ejection Fraction in Persons with Unexplained Dyspnea
The simple, validated H₂FPEF scoring system based on clinical and echocardiographic parameters, developed by experts from the Mayo Clinic, allows the differentiation of heart failure with preserved ejection fraction (HFpEF) from dyspnea of other etiologies and helps decide whether further examinations are necessary. The score can be calculated online and in the Czech language.
News Cenobamate − A Case Study from Slovak Real Practice
Cenobamate is indicated for adjunctive therapy of focal seizures with or without secondary generalization in adult patients who have not achieved sufficient results with previous treatment with at least 2 antiepileptics. This new anti-seizure medication with a dual mechanism of action thus brings another therapeutic option for patients refractory to treatment. At the November 34th Slovak-Czech Epileptology Congress in Bratislava, during a symposium titled “Is there hope for a quality life with epilepsy?” doc. MUDr. Eva Feketeová, PhD., from the Neurological Clinic LF UPJŠ and UNLP in Košice shared her first experiences with cenobamate in clinical practice.
News KDIGO: The Choice of Dialysis Modality Must Consider Patient Individuality
The moment of initiating dialysis, as well as the period immediately before and after it, is crucial for good treatment outcomes. But what exactly can be considered a good outcome, and do the perspectives of doctors and patients align on this issue? Leading nephrologists worldwide discussed this at the KDIGO conference, which was specifically focused on controversies in dialysis treatment.
News Educational Quiz (For Downtime)
The following quiz has been prepared for you as an activity for relaxation and unwinding from today's hectic days. In an easy manner, it will refresh your knowledge about immune cells and may even offer some education or entertainment.